US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cohen & Steers

81.96

+0.01000.01%

Post-market: 81.960.00000.00%16:20 EDT

Volume:153.50K

Turnover:12.58M

Market Cap:4.18B

PE:26.80

High:82.34

Open:81.47

Low:81.47

Close:81.95

Loading ...

Overview Company News Filings

Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for March 2025

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Axsome Therapeutics: Promising CNS Pipeline and Growth Potential Justify Buy Rating

Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders

ACCESS Newswire

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Press Release: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines to Participate in Upcoming April Conferences

Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025

Argent soars as cannabinoid-based epilepsy drug gains approval in Germany

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CNS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNS\",,,,,undefined,":{"symbol":"CNS","market":"US","secType":"STK","nameCN":"Cohen & Steers","latestPrice":81.96,"timestamp":1747252800000,"preClose":81.95,"halted":0,"volume":153496,"hourTrading":{"tag":"盘后","latestPrice":81.96,"preClose":81.96,"latestTime":"16:20 EDT","volume":3069,"amount":251535.24,"timestamp":1747254000910},"delay":0,"floatShares":27543702,"shares":50979157,"eps":3.05822,"marketStatus":"Closed","change":0.01,"latestTime":"05-14 16:00:00 EDT","open":81.47,"high":82.34,"low":81.47,"amount":12583506.71385,"amplitude":0.010616,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.05822,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747296000000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1092369600000,"exchange":"NYSE","adjPreClose":81.95,"dividendRate":0.029161,"preHourTrading":{"tag":"盘前","latestPrice":77.43,"preClose":81.95,"latestTime":"09:28 EDT","volume":25,"amount":1940.27,"timestamp":1747229307305},"postHourTrading":{"tag":"盘后","latestPrice":81.96,"preClose":81.96,"latestTime":"16:20 EDT","volume":3069,"amount":251535.24,"timestamp":1747254000910},"volumeRatio":0.841293,"impliedVol":0.0069,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNS\",,,,,undefined,":{"symbol":"CNS","floatShares":27543702,"roa":"14.72%","roe":"30.76%","lyrEps":3.000753,"volumeRatio":0.841293,"shares":50979157,"dividePrice":2.39,"high":82.34,"amplitude":0.010616,"preClose":81.95,"low":81.47,"week52Low":67.09,"pbRate":"8.23","psRate":"7.90","week52High":110.67,"institutionHeld":0.6018,"latestPrice":81.96,"eps":3.05822,"divideRate":0.029161,"volume":153496,"delay":0,"ttmEps":3.05822,"open":81.47,"prevYearClose":92.34,"prevWeekClose":80.32,"prevMonthClose":76.32,"prevQuarterClose":80.25,"fiveDayClose":77.68,"twentyDayClose":74.7,"sixtyDayClose":86.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526829306","title":"Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526829306","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526829306?lang=en_us&edition=fundamental","pubTime":"2025-04-09 05:45","pubTimestamp":1744148700,"startTime":"0","endTime":"0","summary":"NEW YORK, April 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc.  today reported preliminary assets under management of $87.6 billion as of March 31, 2025, a decrease of $979 million from assets under management of $88.6 billion at February 28, 2025. The decrease was due to market depreciation of $1.1 billion and distributions of $301 million, partially offset by net inflows of $452 million.About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cohen-steers-announces-preliminary-assets-214500049.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cohen-steers-announces-preliminary-assets-214500049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4135"],"gpt_icon":0},{"id":"2526840453","title":"NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2526840453","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526840453?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., April  08, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057991/0/en/NeOnc-Technologies-Announces-Near-Completion-of-Phase-I-Enrollment-for-NEO212-Brain-Cancer-Therapy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007","CNS","BK4135"],"gpt_icon":0},{"id":"2526495398","title":"Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2526495398","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526495398?lang=en_us&edition=fundamental","pubTime":"2025-04-09 01:30","pubTimestamp":1744133400,"startTime":"0","endTime":"0","summary":"DUBLIN, April 08, 2025  -- Avadel Pharmaceuticals plc , a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.The Company provided an update on patient demand metrics that was in line with guidance from its full-year results announcement on March 3, 2025. It also addressed questions related to the recent developments in United States tariff policy and the potential impact on the biopharmaceutical sector, including Avadel.In Q1 2025 patient demand metrics for LUMRYZ, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 2024. These improvements include patient enrollments, patient starts, persistency rates, and net patients on therapy.REVITALYZ, the Company’s Phase 3 pivotal trial studying LUMRYZ in Idiopathic Hypersomnia , is on track to complete enrollment in the second half of 2025.The FDA approval of LUMRYZ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avadel-pharmaceuticals-provides-needham-virtual-173000248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","IH","BK4563","BK4135","AVDL","BK4007","BK4137","CNS","BK4085","BK4510"],"gpt_icon":0},{"id":"2525814141","title":"Cerevance Presents Positive Results from Phase 1 Study of CVN293 at American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525814141","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525814141?lang=en_us&edition=fundamental","pubTime":"2025-04-08 23:00","pubTimestamp":1744124400,"startTime":"0","endTime":"0","summary":"CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative diseases characterized by neuroinflam","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057821/0/en/Cerevance-Presents-Positive-Results-from-Phase-1-Study-of-CVN293-at-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4135","CNS","AAN","CSF","BK4117","BK4107","BK4178"],"gpt_icon":0},{"id":"2525899331","title":"Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899331?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"BOSTON, April 08, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies  including:. The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs. The EMERALD study evaluating relutrigine for broader DEEs. The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE. To RSVP and attend the live event, you may click here. A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-hold-virtual-120000767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MDCO","BK4135","ASO","PRAX","CNS","BK4200","BK4561"],"gpt_icon":0},{"id":"2525301085","title":"Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525301085","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525301085?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:00","pubTimestamp":1744027200,"startTime":"0","endTime":"0","summary":"- Analysis of RISE-PD presented at AAN 2025 showed CREXONT treatment significantly improved patients’ Parkinson’s Disease Sleep Scale-2  total and sub-scale scores. - Treatment with CREXONT also resulted in significantly more patients waking up in an \"On\" state compared to immediate-release CD/LD patients, as part of separate study analysis. BRIDGEWATER, N.J., April 07, 2025----Amneal Pharmaceuticals, Inc.  , a global biopharmaceutical company, today announced a new analysis of the pivotal RISE-PD Phase 3 study showed that patients who successfully converted to CREXONT from immediate release  carbidopa/levodopa  experienced statistically significant improvements in sleep quality. These improvements were measured by their Parkinson’s Disease Sleep Scale-2  total scores, showing a mean difference of -2.35 .A separate analysis of Hauser diary entries, which is a commonly used PD symptom tracking tool, from patients who completed the RISE-PD study will also be presented at AAN. Treatment w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amneal-announces-data-phase-3-120000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169590202.USD","BK4585","CNS","BK4178","BK4161","SG9999001440.SGD","AMRX","LU0256863811.USD","LU0417517546.SGD","BK4116","PD","LU1169589451.USD","BK4588","BK4007","CD","AAN","BK4135","LU1978683503.SGD","BK4023","LU0124384867.USD","IR","LU0256863902.USD"],"gpt_icon":0},{"id":"2525141570","title":"TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals","url":"https://stock-news.laohu8.com/highlight/detail?id=2525141570","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525141570?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:30","pubTimestamp":1744025400,"startTime":"0","endTime":"0","summary":"NEW YORK, April  07, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056593/8790/en/TG-Therapeutics-Announces-Two-Publications-Highlighting-BRIUMVI-in-Medical-Journals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4139","LU2028103732.USD","LU0098860793.USD","LU1732800096.USD","LU1732799900.SGD","BK4153","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4588","BK4585","LU2111349929.HKD","BK4534","LU0158827781.USD","LU1989772840.SGD","TG","BK4090","LU1074936037.SGD","LU1548497426.USD","BK4504","LU2089283258.USD","EC","LU1668664300.SGD","LU2347655156.SGD","BK4516","LU0320765646.SGD","BK4135","LU0158827948.USD","LU0225283273.USD","LU0006306889.USD","LU2089284900.SGD","CNS","LU1162221912.USD","LU1363072403.SGD","LU1989772923.USD","PML","LU0106831901.USD","BK4127","LU0314104364.USD","BK4201","LU0267386448.USD","LU0795875086.SGD","LU0106261372.USD","LU0795875169.SGD","LU1720051017.SGD","LU1720051108.HKD","LU2271345857.HKD","LU0971096721.USD","TGTX","LU2357305700.SGD"],"gpt_icon":0},{"id":"2525190230","title":"Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2525190230","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525190230?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:00","pubTimestamp":1744023600,"startTime":"0","endTime":"0","summary":"TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant improvement","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/07/3056558/28908/en/Tonix-Pharmaceuticals-Presented-Data-and-Analyses-of-TNX-102-SL-Treatment-Effects-on-Fibromyalgia-at-the-American-Academy-of-Pain-Medicine-AAPM-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4583","TNXP","BK4117","BK4107","BK4139","BK4135","CNS"],"gpt_icon":1},{"id":"2525704081","title":"Axsome Therapeutics: Promising CNS Pipeline and Growth Potential Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2525704081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525704081?lang=en_us&edition=fundamental","pubTime":"2025-04-07 08:35","pubTimestamp":1743986114,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics (AXSM) has received a new Buy rating, initiated by Jefferies analyst, Andrew Tsai. Andrew Tsai’s rating is based on Axsome Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-promising-cns-pipeline-and-growth-potential-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/axsome-therapeutics-promising-cns-pipeline-and-growth-potential-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNS","AXSM"],"gpt_icon":0},{"id":"2525862088","title":"Sea Pharmaceuticals Announces Strategic Relationship to Advance Treatments For Patients with CNS Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2525862088","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525862088?lang=en_us&edition=fundamental","pubTime":"2025-04-07 06:05","pubTimestamp":1743977100,"startTime":"0","endTime":"0","summary":"Sea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS . Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug -enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS . Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA. Inotiv Inc will assist Sea to quantify SPM-0404 levels in Clinical Phase 1 and Ph.1b Trials. J.P. Pearson PhD, CEO and Founder of Sea Pharmaceuticals LLC said: \"Sea is thrilled to work with Inotiv Inc., a company that has contributed to the development of many safe and effective medicines approved worldwide including development work of hundreds of IND molecules.\". Tinnitus patients and S-ALS patients urgently need effective and safe medicines. And a continued need exists for more effective and better t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sea-pharmaceuticals-announces-strategic-relationship-220500088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FLS","CNS","BK4585","BK4121","BK4161","JAAA","NOTV","BK4588","LU0054578231.USD","BK4135"],"gpt_icon":0},{"id":"2525164427","title":"Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525164427","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525164427?lang=en_us&edition=fundamental","pubTime":"2025-04-05 23:30","pubTimestamp":1743867000,"startTime":"0","endTime":"0","summary":"ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference. Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer’s disease. NEW YORK, April 05, 2025  -- Anavex Life Sciences Corp.  , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system  disorders, today announced that over three years of continuous treatment with blarcamesine  demonstrated significantly amelioration on clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. ATTENTION-AD  trial result was presented at the AD/PDTM 2025 Conference.The ATTENTION-AD  trial followed the 48-week ANAVEX2-73-AD-004 double-blind  clinical trial, lastin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anavex-life-sciences-announces-positive-153000173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4134","AVXL","BK4552","BK4566","BK4588","III","BK4135","ECG","BK4585","BK4118","BK4139","DB","BK4129"],"gpt_icon":0},{"id":"2524205270","title":"Press Release: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205270","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205270?lang=en_us&edition=fundamental","pubTime":"2025-04-04 20:00","pubTimestamp":1743768000,"startTime":"0","endTime":"0","summary":"DALLAS, April 04, 2025  -- Taysha Gene Therapies, Inc.  , a clinical-stage biotechnology company focused on advancing adeno-associated virus -based gene therapies for severe monogenic diseases of the central nervous system , today announced that, on April 1, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 822,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635.The stock options have an exercise price of $1.265 which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","NQmain","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4139",".IXIC","BK4585","CNS","IE00BGHQF748.EUR","IE00BKPKM429.USD","TSHA","LU2210150020.SGD","NDAQ","BK4588","BK4112","LU2095319765.USD"],"gpt_icon":0},{"id":"2524128362","title":"Praxis Precision Medicines to Participate in Upcoming April Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524128362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524128362?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:00","pubTimestamp":1743714000,"startTime":"0","endTime":"0","summary":"BOSTON, April 03, 2025  -- Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system  disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:. Praxis management will be presenting a corporate overview at the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on Monday, April 7, 2025 at 11:00a.m. EDT. A live webcast of the event will be available through this link.Praxis management will also be participating in the Piper Sandler Spring Biopharma Symposium, taking place at One Boston Place in Boston on Thursday, April 17, 2025.The Company will be available for one-on-one meetings during both events. Interested investors should contact their respective Needham and/or Piper Sandler representatives to request meetings.Replays of the webcasted events will","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/praxis-precision-medicines-participate-upcoming-210000323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4561","ASO","CNS","MDCO","BK4139","PRAX","BK4200"],"gpt_icon":0},{"id":"2524259822","title":"Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259822","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259822?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:35","pubTimestamp":1743680100,"startTime":"0","endTime":"0","summary":"Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices. SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating  the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.A study evaluated the safety and efficacy of donut-shaped circumferential stereotactic body radiation therapy  delivered using the CyberKnife System for the treatme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/accuray-cyberknife-platform-featured-studies-113500310.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/accuray-cyberknife-platform-featured-studies-113500310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","VS","CNS","BK4082","BK4085","ARAY","SRS"],"gpt_icon":0},{"id":"2524303052","title":"UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524303052","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524303052?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:00","pubTimestamp":1743678000,"startTime":"0","endTime":"0","summary":"24 scientific abstracts reflect UCB's ongoing commitment to improving outcomes for people living with neurological conditions, including rare epilepsies Dravet syndrome and Lennox-Gastaut syndrome, as well as generalized myasthenia gravis and thymidine kinase 2 deficiency.Research includes disease course data of untreated patients with thymidine kinase 2 deficiency from largest international dataset.Also features new data on generalized myasthenia gravis treatments RYSTIGGO1  and ZILBRYSQ2  including an open-label extension study investigating rozanolixizumab self-administration and a phase 3 study on the effect of zilucoplan on specific outcome scores.\"We at UCB are deeply committed to driving innovation to improve the treatment and care of people living with severe neurological and neuromuscular conditions such as epilepsy, gMG, and TK2d. The data presented at AAN is a testament to our dedication to exploring new frontiers of science and improving care in areas of high unmet need. It","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ucb-presents-latest-research-across-110000212.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ucb-presents-latest-research-across-110000212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4178","UCBJY","UCBJF","BK4213","AAN","BK4007","BK4585","AFG","FFA","MP","UCB","SD","BK4107","CNS","BK4588","BK4211","BK4135","BK4168","BK4117","IE00BD6J9T35.USD"],"gpt_icon":0},{"id":"2524017834","title":"Argent soars as cannabinoid-based epilepsy drug gains approval in Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2524017834","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524017834?lang=en_us&edition=fundamental","pubTime":"2025-04-03 11:45","pubTimestamp":1743651924,"startTime":"0","endTime":"0","summary":"Argent’s cannabinoid-based therapy for refractory epilepsy, CannEpil, has been approved for prescription in Germany. Epilespy affects around 816,000 people in Germany, with high demand for innovative treatments. Approval of CannEpil in Germany marks significant milestone expansion in Argent’s European market strategy. cutting-edge medical solutions.With SAS approval in place, Argent plans to initiate physician education programs across Germany.It will also expand CannEpil distribution and accessibility through key German partners.Argent will also continue regulatory efforts to gain approval in additional EU markets, while monitoring market uptake and patient outcomes in Germany to support ongoing R&D.CEO and managing director Roby Zomer said the German approval of CannEpil represented a significant milestone for Argent BioPharma and patients who rely on innovative treatments for epilepsy.“This marks our continued expansion in Europe and reinforces our commitment to improving lives thro","market":"nz","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-171259581-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/04/GettyImages-171259581-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/argent-soars-as-cannabinoid-based-epilepsy-drug-gains-approval-in-germany/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["CNS","BK4135"],"gpt_icon":0},{"id":"2524494594","title":"CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2524494594","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524494594?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:46","pubTimestamp":1743597995,"startTime":"0","endTime":"0","summary":"Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks.Make smarter investments with  weekly expert stock picks from the Smart Investor Newsletter.Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts. Biotech Alert: Searches spiking for these stocks today. CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBM. Morning Movers: Mobileye jumps following Volkswagen ADAS partnership","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-fy24-eps-124635719.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-fy24-eps-124635719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","CNSP"],"gpt_icon":0},{"id":"2524121657","title":"Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524121657","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524121657?lang=en_us&edition=fundamental","pubTime":"2025-04-02 04:30","pubTimestamp":1743539400,"startTime":"0","endTime":"0","summary":"Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053815/0/en/Castle-Biosciences-to-Present-New-Data-at-EADO-Supporting-the-Clinical-Value-of-the-DecisionDx-Melanoma-Test-in-Guiding-Risk-Aligned-Management-of-Patients-with-Melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CM","CNS","BK4207","BK4135","SLN","BK4139"],"gpt_icon":0},{"id":"2524115923","title":"CNS Pharmaceuticals Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524115923","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524115923?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:05","pubTimestamp":1743509100,"startTime":"0","endTime":"0","summary":"Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy data in glioblastoma multiforme  for treatment of brain malignancies. CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study potentially focused on the registration of TPI 287 in recurrent GBM in 2025.The Company recently reported results from the primary analysis of Berubicin in second line treatment of glioblastoma multiforme . The trial compared Berubicin to Lomustine, a current standard of care in GBM. The analysis did not demonstrate statistically significant superiority in overall survival, the primary endpoint. However, although the trial was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cns-pharmaceuticals-reports-full-2024-120500175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","OS","BK4135","BK4007","PFS","BK4097","BK4195","CNSP","BK4211"],"gpt_icon":0},{"id":"2524619454","title":"Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524619454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524619454?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053170/33090/en/Axsome-Therapeutics-Announces-Topline-Results-of-PARADIGM-Phase-3-Proof-of-Concept-Trial-of-Solriamfetol-in-Major-Depressive-Disorder-MDD-with-and-without-Excessive-Daytime-Sleepin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4597","BK4215","BK4588","CNS","ESS","PACI.U","BK4135","BK4007","ABVC","ADHD","BK4139","AXSM","BK4505"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNS\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"CNS","amount":0.62,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-12","defaultRemindTime":1747056600000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-22","payableDate":"2025-05-12","currency":"USD","dateTimestamp":1747022400000,"payDate":"2025-05-22"},{"date":"2025-04-16","symbol":"CNS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":null,"defaultRemindTime":1744833600000,"name":null,"time":"Post Market","dateTimestamp":1744776000000,"actualEps":null},{"date":"2025-03-03","symbol":"CNS","amount":0.62,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-13","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-13"},{"market":"US","date":"2025-01-22","symbol":"CNS","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1737522000000,"reportTimeType":"post","actualEps":0.78},{"date":"2024-11-18","symbol":"CNS","amount":0.59,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-18","defaultRemindTime":1731940200000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-02","payableDate":"2024-11-18","currency":"USD","dateTimestamp":1731906000000,"payDate":"2024-12-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNS\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-29","recordDate":"2015-06-02","paymentDate":"2015-06-25","value":0.25,"currency":"USD"},{"executeDate":"2015-09-01","recordDate":"2015-09-03","paymentDate":"2015-09-24","value":0.25,"currency":"USD"},{"executeDate":"2015-11-23","recordDate":"2015-11-25","paymentDate":"2015-12-16","value":0.75,"currency":"USD"},{"executeDate":"2016-03-07","recordDate":"2016-03-09","paymentDate":"2016-03-23","value":0.26,"currency":"USD"},{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-06-23","value":0.26,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1729137600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNS","date":"2025-05-13","current":26.90187,"percent":0.523064,"low":12.87852,"twenty":18.128761,"median":26.319683,"eighty":33.522419,"high":43.702499,"avg":26.244172,"sd":7.577416,"marketCap":4224642740},"quantilePoints":[{"date":"2020-05-15","current":23.172849,"twenty":17.91219,"median":21.888209,"eighty":25.763067,"marketCap":2842149887},{"date":"2020-05-22","current":24.878682,"twenty":17.91219,"median":21.888209,"eighty":25.763067,"marketCap":3051370333},{"date":"2020-05-29","current":24.75016,"twenty":17.91219,"median":21.888209,"eighty":25.782303,"marketCap":3035607148},{"date":"2020-06-05","current":28.695386,"twenty":17.91219,"median":21.888209,"eighty":25.792568,"marketCap":3519489138},{"date":"2020-06-12","current":26.802613,"twenty":17.91219,"median":21.888209,"eighty":25.860348,"marketCap":3287340424},{"date":"2020-06-19","current":27.643845,"twenty":17.91219,"median":21.929604,"eighty":25.901982,"marketCap":3390517630},{"date":"2020-06-26","current":25.143514,"twenty":17.91219,"median":21.929604,"eighty":25.953213,"marketCap":3083852046},{"date":"2020-07-02","current":26.319683,"twenty":17.91219,"median":21.967124,"eighty":25.986175,"marketCap":3228109065},{"date":"2020-07-10","current":26.152215,"twenty":17.91219,"median":22.016567,"eighty":25.992492,"marketCap":3207569158},{"date":"2020-07-17","current":26.362523,"twenty":17.91219,"median":22.08441,"eighty":26.071486,"marketCap":3233363460},{"date":"2020-07-24","current":25.339106,"twenty":17.91219,"median":22.145224,"eighty":26.111636,"marketCap":3036562493},{"date":"2020-07-31","current":23.987847,"twenty":17.91219,"median":22.179183,"eighty":26.111636,"marketCap":2874631600},{"date":"2020-08-07","current":24.132484,"twenty":17.91219,"median":22.253822,"eighty":26.111636,"marketCap":2891964508},{"date":"2020-08-14","current":24.666724,"twenty":17.935145,"median":22.29366,"eighty":26.111636,"marketCap":2955986191},{"date":"2020-08-21","current":24.654763,"twenty":17.935145,"median":22.345044,"eighty":26.111636,"marketCap":2954552870},{"date":"2020-08-28","current":24.499276,"twenty":17.958411,"median":22.424008,"eighty":26.111636,"marketCap":2935919693},{"date":"2020-09-04","current":23.969023,"twenty":18.000138,"median":22.496172,"eighty":26.111636,"marketCap":2872375785},{"date":"2020-09-11","current":23.263348,"twenty":18.099298,"median":22.501958,"eighty":26.111636,"marketCap":2787809831},{"date":"2020-09-18","current":22.832767,"twenty":18.192403,"median":22.546509,"eighty":26.111636,"marketCap":2736210266},{"date":"2020-09-25","current":22.155,"twenty":18.28108,"median":22.546509,"eighty":26.111636,"marketCap":2654988728},{"date":"2020-10-02","current":22.705187,"twenty":18.403976,"median":22.566583,"eighty":26.111636,"marketCap":2720921506},{"date":"2020-10-09","current":23.602231,"twenty":18.52773,"median":22.594828,"eighty":26.111636,"marketCap":2828420600},{"date":"2020-10-16","current":23.598244,"twenty":18.562573,"median":22.670837,"eighty":26.111636,"marketCap":2827942826},{"date":"2020-10-23","current":23.437391,"twenty":18.624451,"median":22.7205,"eighty":26.111636,"marketCap":2759143406},{"date":"2020-10-30","current":22.852978,"twenty":18.788661,"median":22.762059,"eighty":26.111636,"marketCap":2690343986},{"date":"2020-11-06","current":23.997588,"twenty":18.837817,"median":22.78812,"eighty":26.111636,"marketCap":2825092062},{"date":"2020-11-13","current":25.820138,"twenty":18.884452,"median":22.835905,"eighty":26.122473,"marketCap":3039649967},{"date":"2020-11-20","current":28.109489,"twenty":18.914144,"median":22.857139,"eighty":26.15386,"marketCap":3309161456},{"date":"2020-11-27","current":29.432766,"twenty":18.924936,"median":22.889551,"eighty":26.180357,"marketCap":3464942919},{"date":"2020-12-04","current":30.557145,"twenty":18.972497,"median":22.931471,"eighty":26.234833,"marketCap":3597309378},{"date":"2020-12-11","current":30.5815,"twenty":19.026142,"median":22.993772,"eighty":26.256821,"marketCap":3600176521},{"date":"2020-12-18","current":30.191823,"twenty":19.058337,"median":23.028301,"eighty":26.31233,"marketCap":3554302225},{"date":"2020-12-24","current":29.794029,"twenty":19.093721,"median":23.060018,"eighty":26.337042,"marketCap":3507472215},{"date":"2020-12-31","current":30.15935,"twenty":19.103205,"median":23.125625,"eighty":26.362312,"marketCap":3550479367},{"date":"2021-01-08","current":29.091799,"twenty":19.162181,"median":23.160033,"eighty":26.401457,"marketCap":3424802910},{"date":"2021-01-15","current":29.887389,"twenty":19.202231,"median":23.200606,"eighty":26.441488,"marketCap":3518462931},{"date":"2021-01-22","current":29.74126,"twenty":19.221971,"median":23.235659,"eighty":26.487931,"marketCap":3501260070},{"date":"2021-01-29","current":40.869698,"twenty":19.278958,"median":23.263348,"eighty":26.526288,"marketCap":3129964987},{"date":"2021-02-05","current":42.298578,"twenty":19.312251,"median":23.304616,"eighty":26.539566,"marketCap":3239394297},{"date":"2021-02-12","current":43.072294,"twenty":19.369502,"median":23.346381,"eighty":26.568376,"marketCap":3298648596},{"date":"2021-02-19","current":41.312714,"twenty":19.404944,"median":23.412011,"eighty":26.604536,"marketCap":3163892852},{"date":"2021-02-26","current":40.543706,"twenty":19.462875,"median":23.44404,"eighty":26.627953,"marketCap":3104999179},{"date":"2021-03-05","current":41.494638,"twenty":19.519205,"median":23.521823,"eighty":26.663067,"marketCap":3177825348},{"date":"2021-03-12","current":42.773043,"twenty":19.606366,"median":23.562376,"eighty":26.674223,"marketCap":3275730727},{"date":"2021-03-19","current":41.356092,"twenty":19.606366,"median":23.598948,"eighty":26.704024,"marketCap":3167214913},{"date":"2021-03-26","current":40.990833,"twenty":19.607142,"median":23.626615,"eighty":26.73796,"marketCap":3139241947},{"date":"2021-04-01","current":42.307023,"twenty":19.607142,"median":23.674531,"eighty":26.795994,"marketCap":3240041082},{"date":"2021-04-09","current":41.878789,"twenty":19.606366,"median":23.704202,"eighty":26.872012,"marketCap":3207245191},{"date":"2021-04-16","current":42.502248,"twenty":19.606366,"median":23.710206,"eighty":26.913332,"marketCap":3254992149},{"date":"2021-04-23","current":31.693219,"twenty":19.606366,"median":23.710206,"eighty":27.029751,"marketCap":3323477686},{"date":"2021-04-30","current":31.283888,"twenty":19.606366,"median":23.755094,"eighty":27.056161,"marketCap":3280553653},{"date":"2021-05-07","current":32.560979,"twenty":19.606366,"median":23.782134,"eighty":27.213028,"marketCap":3414474551},{"date":"2021-05-14","current":33.61905,"twenty":19.606366,"median":23.8007,"eighty":27.25402,"marketCap":3525428090},{"date":"2021-05-21","current":33.200422,"twenty":19.606366,"median":23.839623,"eighty":27.262589,"marketCap":3481529081},{"date":"2021-05-28","current":33.642052,"twenty":19.606366,"median":23.883463,"eighty":27.340067,"marketCap":3527840123},{"date":"2021-06-04","current":34.226291,"twenty":19.606366,"median":23.921975,"eighty":27.431277,"marketCap":3589105773},{"date":"2021-06-11","current":34.424104,"twenty":19.606366,"median":23.95944,"eighty":27.60508,"marketCap":3609849261},{"date":"2021-06-18","current":35.633985,"twenty":19.606366,"median":23.983072,"eighty":27.65774,"marketCap":3736722220},{"date":"2021-06-25","current":37.754727,"twenty":19.606366,"median":24.001439,"eighty":27.731371,"marketCap":3959111704},{"date":"2021-07-02","current":37.317698,"twenty":19.606366,"median":24.019996,"eighty":27.803594,"marketCap":3913283069},{"date":"2021-07-09","current":36.871468,"twenty":19.606366,"median":24.065621,"eighty":27.878924,"marketCap":3866489620},{"date":"2021-07-16","current":36.443639,"twenty":19.606366,"median":24.065621,"eighty":27.954254,"marketCap":3821625798},{"date":"2021-07-23","current":32.23161,"twenty":19.606366,"median":24.065621,"eighty":28.3446,"marketCap":3962006144},{"date":"2021-07-30","current":32.655452,"twenty":19.606366,"median":24.065621,"eighty":28.597983,"marketCap":4014106067},{"date":"2021-08-06","current":34.262979,"twenty":19.606366,"median":24.065621,"eighty":28.779046,"marketCap":4211708107},{"date":"2021-08-13","current":34.608395,"twenty":19.606366,"median":24.065621,"eighty":28.919847,"marketCap":4254167761},{"date":"2021-08-20","current":34.376809,"twenty":19.606366,"median":24.065621,"eighty":29.018684,"marketCap":4225700493},{"date":"2021-08-27","current":34.690824,"twenty":19.606366,"median":24.065621,"eighty":29.125292,"marketCap":4264300178},{"date":"2021-09-03","current":34.518116,"twenty":19.606366,"median":24.065621,"eighty":29.237927,"marketCap":4243070351},{"date":"2021-09-10","current":34.015692,"twenty":19.606366,"median":24.065621,"eighty":29.325721,"marketCap":4181310855},{"date":"2021-09-17","current":34.235502,"twenty":19.606366,"median":24.065621,"eighty":29.428707,"marketCap":4208330635},{"date":"2021-09-24","current":33.650649,"twenty":19.606366,"median":24.065621,"eighty":29.513948,"marketCap":4136438722},{"date":"2021-10-01","current":33.485791,"twenty":19.606366,"median":24.065621,"eighty":29.715133,"marketCap":4116173887},{"date":"2021-10-08","current":33.897936,"twenty":19.607142,"median":24.072911,"eighty":29.833679,"marketCap":4166835974},{"date":"2021-10-15","current":34.282604,"twenty":19.607142,"median":24.072911,"eighty":29.886999,"marketCap":4214120588},{"date":"2021-10-22","current":31.39397,"twenty":19.607142,"median":24.120524,"eighty":29.97263,"marketCap":4473703468},{"date":"2021-10-29","current":32.128708,"twenty":19.607919,"median":24.159112,"eighty":30.0979,"marketCap":4578405113},{"date":"2021-11-05","current":34.01649,"twenty":19.607919,"median":24.231662,"eighty":30.206436,"marketCap":4847417859},{"date":"2021-11-12","current":33.779441,"twenty":19.607919,"median":24.272267,"eighty":30.2663,"marketCap":4813637944},{"date":"2021-11-19","current":33.335822,"twenty":19.607919,"median":24.34227,"eighty":30.314228,"marketCap":4750421245},{"date":"2021-11-26","current":31.585048,"twenty":19.607919,"median":24.388858,"eighty":30.347179,"marketCap":4500932441},{"date":"2021-12-03","current":30.152596,"twenty":19.607919,"median":24.435486,"eighty":30.418709,"marketCap":4296805238},{"date":"2021-12-10","current":30.687649,"twenty":19.607919,"median":24.495428,"eighty":30.555834,"marketCap":4373051333},{"date":"2021-12-17","current":30.917925,"twenty":19.607919,"median":24.535811,"eighty":30.628753,"marketCap":4405866108},{"date":"2021-12-23","current":30.464146,"twenty":19.607919,"median":24.549254,"eighty":30.66128,"marketCap":4341201699},{"date":"2021-12-31","current":31.32768,"twenty":19.607919,"median":24.669496,"eighty":30.712708,"marketCap":4464257105},{"date":"2022-01-07","current":30.782468,"twenty":19.609472,"median":24.728839,"eighty":30.771039,"marketCap":4386563299},{"date":"2022-01-14","current":29.597225,"twenty":19.609472,"median":24.776362,"eighty":30.771039,"marketCap":4217663722},{"date":"2022-01-21","current":28.411981,"twenty":19.609472,"median":24.864401,"eighty":30.771039,"marketCap":4048764145},{"date":"2022-01-28","current":18.641168,"twenty":19.590769,"median":24.917596,"eighty":30.771039,"marketCap":3940668416},{"date":"2022-02-04","current":18.285055,"twenty":19.499836,"median":24.917596,"eighty":30.771039,"marketCap":3865387462},{"date":"2022-02-11","current":18.433435,"twenty":19.415099,"median":24.917596,"eighty":30.771039,"marketCap":3896754526},{"date":"2022-02-18","current":18.221137,"twenty":19.383827,"median":24.917596,"eighty":30.771039,"marketCap":3851875496},{"date":"2022-02-25","current":18.59767,"twenty":19.32955,"median":24.882576,"eighty":30.771039,"marketCap":3931473126},{"date":"2022-03-04","current":17.962167,"twenty":19.282693,"median":24.776362,"eighty":30.771039,"marketCap":3797130353},{"date":"2022-03-11","current":17.870066,"twenty":19.226995,"median":24.690202,"eighty":30.771039,"marketCap":3777660385},{"date":"2022-03-18","current":19.069692,"twenty":19.199701,"median":24.590174,"eighty":30.771039,"marketCap":4031256708},{"date":"2022-03-25","current":19.266364,"twenty":19.165812,"median":24.531824,"eighty":30.771039,"marketCap":4072832201},{"date":"2022-04-01","current":20.194336,"twenty":19.165812,"median":24.414953,"eighty":30.771039,"marketCap":4269001841},{"date":"2022-04-08","current":19.798278,"twenty":19.165812,"median":24.34446,"eighty":30.771039,"marketCap":4185276833},{"date":"2022-04-14","current":19.006163,"twenty":19.164835,"median":24.272267,"eighty":30.771039,"marketCap":4017826818},{"date":"2022-04-22","current":19.515002,"twenty":19.160428,"median":24.159112,"eighty":30.771039,"marketCap":3992027833},{"date":"2022-04-29","current":18.48702,"twenty":19.120759,"median":24.109263,"eighty":30.771039,"marketCap":3781741767},{"date":"2022-05-06","current":18.140576,"twenty":19.097352,"median":24.008501,"eighty":30.771039,"marketCap":3710872529},{"date":"2022-05-13","current":17.343267,"twenty":19.068709,"median":23.966477,"eighty":30.771039,"marketCap":3547773304},{"date":"2022-05-20","current":17.248065,"twenty":19.045263,"median":23.843035,"eighty":30.771039,"marketCap":3528298769},{"date":"2022-05-27","current":18.354779,"twenty":19.014348,"median":23.76195,"eighty":30.771039,"marketCap":3754690232},{"date":"2022-06-03","current":17.897813,"twenty":18.977944,"median":23.679147,"eighty":30.771039,"marketCap":3661212467},{"date":"2022-06-10","current":16.634018,"twenty":18.947577,"median":23.585518,"eighty":30.771039,"marketCap":3402688023},{"date":"2022-06-17","current":15.608226,"twenty":18.914815,"median":23.455654,"eighty":30.689004,"marketCap":3192849914},{"date":"2022-06-24","current":16.260354,"twenty":18.900025,"median":23.315177,"eighty":30.690358,"marketCap":3326250475},{"date":"2022-07-01","current":15.477324,"twenty":18.870215,"median":23.246645,"eighty":30.690358,"marketCap":3166072430},{"date":"2022-07-08","current":15.736747,"twenty":18.832714,"median":23.109571,"eighty":30.614098,"marketCap":3219140536},{"date":"2022-07-15","current":16.162773,"twenty":18.79571,"median":22.956359,"eighty":30.520819,"marketCap":3306289077},{"date":"2022-07-22","current":16.110583,"twenty":18.706811,"median":22.835905,"eighty":30.406577,"marketCap":3382239761},{"date":"2022-07-29","current":17.089231,"twenty":18.655675,"median":22.723109,"eighty":30.285785,"marketCap":3587696099},{"date":"2022-08-05","current":17.336827,"twenty":18.60341,"median":22.666493,"eighty":30.247635,"marketCap":3639676038},{"date":"2022-08-12","current":18.014155,"twenty":18.576102,"median":22.585581,"eighty":30.247635,"marketCap":3781873710},{"date":"2022-08-19","current":17.726522,"twenty":18.553033,"median":22.523144,"eighty":30.247635,"marketCap":3721488397},{"date":"2022-08-26","current":17.097906,"twenty":18.483674,"median":22.467927,"eighty":30.247635,"marketCap":3589517270},{"date":"2022-09-02","current":16.432175,"twenty":18.396609,"median":22.353732,"eighty":30.247635,"marketCap":3449754489},{"date":"2022-09-09","current":17.31595,"twenty":18.356371,"median":22.298527,"eighty":30.247635,"marketCap":3635293233},{"date":"2022-09-16","current":16.842748,"twenty":18.283229,"median":22.249478,"eighty":30.247635,"marketCap":3535949654},{"date":"2022-09-23","current":15.91722,"twenty":18.21193,"median":22.179183,"eighty":30.247635,"marketCap":3341645300},{"date":"2022-09-30","current":14.527769,"twenty":18.176655,"median":22.123505,"eighty":30.247635,"marketCap":3049945280},{"date":"2022-10-07","current":14.019773,"twenty":18.104175,"median":22.045314,"eighty":30.247635,"marketCap":2943297026},{"date":"2022-10-14","current":12.87852,"twenty":18.032153,"median":21.992474,"eighty":30.247635,"marketCap":2703703688},{"date":"2022-10-21","current":13.875906,"twenty":17.988291,"median":21.929604,"eighty":30.247635,"marketCap":2817169639},{"date":"2022-10-28","current":14.518731,"twenty":17.957216,"median":21.836807,"eighty":30.247635,"marketCap":2947679831},{"date":"2022-11-04","current":14.228587,"twenty":17.927938,"median":21.723866,"eighty":30.232415,"marketCap":2888773025},{"date":"2022-11-11","current":16.001462,"twenty":17.901888,"median":21.670268,"eighty":30.232415,"marketCap":3248712878},{"date":"2022-11-18","current":15.814339,"twenty":17.857353,"median":21.62555,"eighty":30.232415,"marketCap":3210721932},{"date":"2022-11-25","current":15.672797,"twenty":17.824307,"median":21.559545,"eighty":30.232415,"marketCap":3181985192},{"date":"2022-12-02","current":16.212576,"twenty":17.737907,"median":21.517024,"eighty":30.232415,"marketCap":3291574457},{"date":"2022-12-09","current":16.03025,"twenty":17.634502,"median":21.398073,"eighty":30.232415,"marketCap":3254557638},{"date":"2022-12-16","current":15.432895,"twenty":17.536399,"median":21.363322,"eighty":30.232415,"marketCap":3133278852},{"date":"2022-12-23","current":15.157007,"twenty":17.453772,"median":21.291372,"eighty":30.232415,"marketCap":3077266561},{"date":"2022-12-30","current":15.488072,"twenty":17.435795,"median":21.271518,"eighty":30.232415,"marketCap":3144481310},{"date":"2023-01-06","current":16.500458,"twenty":17.354712,"median":21.218395,"eighty":30.232415,"marketCap":3350022065},{"date":"2023-01-13","current":17.735954,"twenty":17.299707,"median":21.152857,"eighty":30.232415,"marketCap":3600859716},{"date":"2023-01-20","current":17.532037,"twenty":17.272433,"median":21.104444,"eighty":30.232415,"marketCap":3559459327},{"date":"2023-01-27","current":20.240915,"twenty":17.272433,"median":21.102629,"eighty":30.232415,"marketCap":3462046647},{"date":"2023-02-03","current":21.659032,"twenty":17.272433,"median":21.116232,"eighty":30.232415,"marketCap":3704604220},{"date":"2023-02-10","current":21.055336,"twenty":17.272433,"median":21.15785,"eighty":30.232415,"marketCap":3601346779},{"date":"2023-02-17","current":21.129374,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3614010428},{"date":"2023-02-24","current":20.698656,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3540339494},{"date":"2023-03-03","current":20.580952,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3520207189},{"date":"2023-03-10","current":18.634532,"twenty":17.272433,"median":21.15785,"eighty":30.232415,"marketCap":3187287608},{"date":"2023-03-17","current":18.169458,"twenty":17.272433,"median":21.116232,"eighty":30.232415,"marketCap":3107740452},{"date":"2023-03-24","current":17.469835,"twenty":17.272433,"median":21.115136,"eighty":30.232415,"marketCap":2988075455},{"date":"2023-03-31","current":18.362705,"twenty":17.273887,"median":21.10979,"eighty":30.224296,"marketCap":3140793856},{"date":"2023-04-06","current":17.72248,"twenty":17.272433,"median":21.115136,"eighty":30.232415,"marketCap":3031288379},{"date":"2023-04-14","current":17.659318,"twenty":17.270978,"median":21.115684,"eighty":30.240533,"marketCap":3020485148},{"date":"2023-04-20","current":18.415569,"twenty":17.270978,"median":21.115684,"eighty":30.240533,"marketCap":3026377819},{"date":"2023-04-28","current":17.701417,"twenty":17.269524,"median":21.116232,"eighty":30.248652,"marketCap":2909015447},{"date":"2023-05-05","current":16.207374,"twenty":17.258712,"median":21.116232,"eighty":30.248652,"marketCap":2663487472},{"date":"2023-05-12","current":16.342745,"twenty":17.216458,"median":21.122803,"eighty":30.25677,"marketCap":2685734018},{"date":"2023-05-19","current":16.937516,"twenty":17.1325,"median":21.129374,"eighty":30.263026,"marketCap":2783477447},{"date":"2023-05-26","current":16.037888,"twenty":17.093405,"median":21.143612,"eighty":30.269283,"marketCap":2635634371},{"date":"2023-06-01","current":16.262047,"twenty":17.038241,"median":21.15785,"eighty":30.275539,"marketCap":2672472347},{"date":"2023-06-09","current":18.405015,"twenty":17.00976,"median":21.159455,"eighty":30.288052,"marketCap":3024643395},{"date":"2023-06-16","current":18.36915,"twenty":17.00976,"median":21.159455,"eighty":30.288052,"marketCap":3018749319},{"date":"2023-06-23","current":17.173631,"twenty":16.999409,"median":21.167314,"eighty":30.322625,"marketCap":2822280115},{"date":"2023-06-30","current":17.421701,"twenty":16.956799,"median":21.19089,"eighty":30.357198,"marketCap":2863047475},{"date":"2023-07-07","current":17.176619,"twenty":16.955322,"median":21.194819,"eighty":30.374484,"marketCap":2822771288},{"date":"2023-07-14","current":19.140259,"twenty":16.955322,"median":21.194819,"eighty":30.374484,"marketCap":3145471956},{"date":"2023-07-21","current":22.272461,"twenty":16.9482,"median":21.240006,"eighty":30.381903,"marketCap":3210797966},{"date":"2023-07-28","current":22.401932,"twenty":16.944638,"median":21.281264,"eighty":30.385612,"marketCap":3229462540},{"date":"2023-08-04","current":21.798869,"twenty":16.944638,"median":21.362879,"eighty":30.385612,"marketCap":3142524917},{"date":"2023-08-11","current":22.605317,"twenty":16.944638,"median":21.393729,"eighty":30.385612,"marketCap":3258782486},{"date":"2023-08-18","current":21.616995,"twenty":16.944638,"median":21.462546,"eighty":30.385612,"marketCap":3116305941},{"date":"2023-08-25","current":21.323906,"twenty":16.944638,"median":21.480607,"eighty":30.385612,"marketCap":3074054276},{"date":"2023-09-01","current":22.213396,"twenty":16.941077,"median":21.556303,"eighty":30.389322,"marketCap":3202283166},{"date":"2023-09-08","current":21.569282,"twenty":16.941077,"median":21.60996,"eighty":30.389322,"marketCap":3109427763},{"date":"2023-09-15","current":21.882819,"twenty":16.941077,"median":21.616127,"eighty":30.389322,"marketCap":3154627219},{"date":"2023-09-22","current":21.061489,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":3036224297},{"date":"2023-09-29","current":21.156914,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":3049980653},{"date":"2023-10-05","current":20.373072,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":2936982014},{"date":"2023-10-13","current":19.302957,"twenty":16.962706,"median":21.62555,"eighty":30.393031,"marketCap":2782714307},{"date":"2023-10-20","current":19.766808,"twenty":17.094797,"median":21.635278,"eighty":30.394386,"marketCap":2603881679},{"date":"2023-10-27","current":19.173804,"twenty":17.14802,"median":21.654483,"eighty":30.398449,"marketCap":2525765228},{"date":"2023-11-03","current":20.624613,"twenty":17.21745,"median":21.654483,"eighty":30.398449,"marketCap":2716880317},{"date":"2023-11-10","current":19.788994,"twenty":17.261187,"median":21.654483,"eighty":30.398449,"marketCap":2606804215},{"date":"2023-11-17","current":21.859285,"twenty":17.306392,"median":21.660629,"eighty":30.398449,"marketCap":2879523600},{"date":"2023-11-24","current":21.113234,"twenty":17.347082,"median":21.667395,"eighty":30.398449,"marketCap":2781246344},{"date":"2023-12-01","current":21.818252,"twenty":17.382449,"median":21.672805,"eighty":30.398449,"marketCap":2874118351},{"date":"2023-12-08","current":23.530438,"twenty":17.431804,"median":21.701465,"eighty":30.398449,"marketCap":3099664654},{"date":"2023-12-15","current":27.555382,"twenty":17.450036,"median":21.745585,"eighty":30.398449,"marketCap":3629870450},{"date":"2023-12-22","current":27.365139,"twenty":17.496342,"median":21.810744,"eighty":30.398449,"marketCap":3604809750},{"date":"2023-12-29","current":28.827398,"twenty":17.527254,"median":21.852697,"eighty":30.399804,"marketCap":3797433171},{"date":"2024-01-05","current":26.820522,"twenty":17.571979,"median":21.883893,"eighty":30.40319,"marketCap":3533067353},{"date":"2024-01-12","current":25.46644,"twenty":17.607846,"median":21.929604,"eighty":30.40319,"marketCap":3354694133},{"date":"2024-01-19","current":24.690547,"twenty":17.644846,"median":21.986315,"eighty":30.406577,"marketCap":3252485787},{"date":"2024-01-26","current":26.760864,"twenty":17.711966,"median":22.045314,"eighty":30.40319,"marketCap":3453462775},{"date":"2024-02-02","current":27.042638,"twenty":17.738956,"median":22.116155,"eighty":30.40319,"marketCap":3489825360},{"date":"2024-02-09","current":26.34582,"twenty":17.7688,"median":22.15546,"eighty":30.40319,"marketCap":3399901671},{"date":"2024-02-16","current":27.141639,"twenty":17.80097,"median":22.213396,"eighty":30.40319,"marketCap":3502601403},{"date":"2024-02-23","current":27.30918,"twenty":17.835673,"median":22.249478,"eighty":30.40319,"marketCap":3524222400},{"date":"2024-03-01","current":28.224884,"twenty":17.840133,"median":22.284274,"eighty":30.399804,"marketCap":3642393114},{"date":"2024-03-08","current":29.072974,"twenty":17.854544,"median":22.345044,"eighty":30.399804,"marketCap":3751838236},{"date":"2024-03-15","current":26.943156,"twenty":17.854544,"median":22.410631,"eighty":30.399804,"marketCap":3476987362},{"date":"2024-03-22","current":29.203449,"twenty":17.862113,"median":22.484099,"eighty":30.399804,"marketCap":3768675948},{"date":"2024-03-28","current":29.116605,"twenty":17.870066,"median":22.523144,"eighty":30.399804,"marketCap":3757468730},{"date":"2024-04-05","current":28.065076,"twenty":17.868475,"median":22.583959,"eighty":30.40319,"marketCap":3621769977},{"date":"2024-04-12","current":27.869353,"twenty":17.868475,"median":22.609066,"eighty":30.40319,"marketCap":3596512181},{"date":"2024-04-19","current":25.6312,"twenty":17.868475,"median":22.695824,"eighty":30.40319,"marketCap":3274103832},{"date":"2024-04-26","current":27.635851,"twenty":17.870066,"median":22.753371,"eighty":30.399804,"marketCap":3530175929},{"date":"2024-05-03","current":27.556733,"twenty":17.870066,"median":22.836196,"eighty":30.399804,"marketCap":3520069499},{"date":"2024-05-10","current":29.163628,"twenty":17.870066,"median":22.943915,"eighty":30.399804,"marketCap":3725332736},{"date":"2024-05-17","current":29.183411,"twenty":17.870066,"median":23.090775,"eighty":30.399804,"marketCap":3727859756},{"date":"2024-05-24","current":28.221973,"twenty":17.870066,"median":23.209747,"eighty":30.399804,"marketCap":3605046589},{"date":"2024-05-31","current":27.054795,"twenty":17.870066,"median":23.285328,"eighty":30.399804,"marketCap":3455952415},{"date":"2024-06-07","current":27.822363,"twenty":17.870066,"median":23.445508,"eighty":30.399804,"marketCap":3554000787},{"date":"2024-06-14","current":28.154712,"twenty":17.868475,"median":23.529127,"eighty":30.40319,"marketCap":3596454721},{"date":"2024-06-21","current":28.269451,"twenty":17.866885,"median":23.600941,"eighty":30.406577,"marketCap":3611111437},{"date":"2024-06-28","current":28.00832,"twenty":17.862113,"median":23.655779,"eighty":30.416736,"marketCap":3577754774},{"date":"2024-07-05","current":28.550365,"twenty":17.862113,"median":23.741772,"eighty":30.416736,"marketCap":3646995119},{"date":"2024-07-12","current":29.808544,"twenty":17.862113,"median":23.829483,"eighty":30.416736,"marketCap":3807713585},{"date":"2024-07-15","current":30.034066,"twenty":17.862113,"median":23.84751,"eighty":30.416736,"marketCap":3836521612},{"date":"2024-08-02","current":33.347515,"twenty":17.848785,"median":23.979228,"eighty":30.525101,"marketCap":4259544743},{"date":"2024-08-09","current":32.935122,"twenty":17.848785,"median":24.052267,"eighty":30.630396,"marketCap":4206869033},{"date":"2024-08-16","current":33.287348,"twenty":17.848785,"median":24.123689,"eighty":30.714063,"marketCap":4251859581},{"date":"2024-08-23","current":33.750387,"twenty":17.848785,"median":24.183737,"eighty":30.826419,"marketCap":4311004459},{"date":"2024-08-30","current":34.755617,"twenty":17.848785,"median":24.299974,"eighty":30.970882,"marketCap":4439404451},{"date":"2024-09-06","current":34.79915,"twenty":17.848785,"median":24.36742,"eighty":31.120432,"marketCap":4444965081},{"date":"2024-09-13","current":35.404663,"twenty":17.848785,"median":24.435486,"eighty":31.286647,"marketCap":4522308383},{"date":"2024-09-20","current":37.834627,"twenty":17.848785,"median":24.535811,"eighty":31.405188,"marketCap":4832692616},{"date":"2024-09-27","current":37.620917,"twenty":17.848785,"median":24.628464,"eighty":31.548301,"marketCap":4805394980},{"date":"2024-10-04","current":36.576111,"twenty":17.848785,"median":24.693686,"eighty":31.671335,"marketCap":4671939870},{"date":"2024-10-11","current":36.342613,"twenty":17.848785,"median":24.776362,"eighty":31.921404,"marketCap":4642114675},{"date":"2024-10-18","current":39.372812,"twenty":17.848785,"median":24.882576,"eighty":32.212468,"marketCap":5325566602},{"date":"2024-10-25","current":37.545256,"twenty":17.848785,"median":25.007411,"eighty":32.383174,"marketCap":5078371341},{"date":"2024-10-31","current":37.732123,"twenty":17.848785,"median":25.038793,"eighty":32.531573,"marketCap":5103646930},{"date":"2024-11-08","current":38.195552,"twenty":17.848309,"median":25.036169,"eighty":32.647241,"marketCap":5166330391},{"date":"2024-11-15","current":37.647327,"twenty":17.848309,"median":25.05345,"eighty":32.844946,"marketCap":5092177385},{"date":"2024-11-22","current":38.12203,"twenty":17.848309,"median":25.05345,"eighty":32.996976,"marketCap":5156385738},{"date":"2024-11-29","current":39.120028,"twenty":17.848309,"median":25.05345,"eighty":33.070314,"marketCap":5291374952},{"date":"2024-12-06","current":37.834218,"twenty":17.848309,"median":25.05345,"eighty":33.177608,"marketCap":5117456264},{"date":"2024-12-13","current":37.6249,"twenty":17.848309,"median":25.05345,"eighty":33.254869,"marketCap":5089143920},{"date":"2024-12-20","current":33.890817,"twenty":17.848309,"median":25.143514,"eighty":33.332395,"marketCap":4584071917},{"date":"2024-12-27","current":35.344829,"twenty":17.848309,"median":25.20584,"eighty":33.433016,"marketCap":4780741596},{"date":"2025-01-03","current":34.152464,"twenty":17.848309,"median":25.316828,"eighty":33.484887,"marketCap":4619462348},{"date":"2025-01-10","current":33.449754,"twenty":17.847833,"median":25.412351,"eighty":33.512931,"marketCap":4524413763},{"date":"2025-01-17","current":32.918984,"twenty":17.847833,"median":25.627156,"eighty":33.512931,"marketCap":4452621747},{"date":"2025-01-24","current":29.843666,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4514302211},{"date":"2025-01-31","current":29.689919,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4491045643},{"date":"2025-02-07","current":29.850351,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4515313366},{"date":"2025-02-14","current":28.209267,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4267074775},{"date":"2025-02-21","current":28.924526,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4375268377},{"date":"2025-02-28","current":29.116429,"twenty":17.847833,"median":25.724336,"eighty":33.512931,"marketCap":4404296702},{"date":"2025-03-07","current":28.988386,"twenty":17.846293,"median":25.852331,"eighty":33.522419,"marketCap":4384928194},{"date":"2025-03-14","current":25.446971,"twenty":17.849737,"median":25.966294,"eighty":33.522419,"marketCap":3849236048},{"date":"2025-03-21","current":26.589254,"twenty":17.892782,"median":26.105931,"eighty":33.522419,"marketCap":4022023524},{"date":"2025-03-28","current":26.946428,"twenty":17.939383,"median":26.181536,"eighty":33.522419,"marketCap":4076051467},{"date":"2025-04-04","current":25.986102,"twenty":17.978554,"median":26.303934,"eighty":33.522419,"marketCap":3930787659},{"date":"2025-04-11","current":24.851655,"twenty":18.014155,"median":26.294159,"eighty":33.512931,"marketCap":3759185663},{"date":"2025-04-17","current":23.983353,"twenty":18.072738,"median":26.294159,"eighty":33.512931,"marketCap":3766321745},{"date":"2025-04-25","current":24.944115,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":3917198891},{"date":"2025-05-02","current":24.905165,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":3911082250},{"date":"2025-05-09","current":25.957204,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":4076293393},{"date":"2025-05-13","current":26.90187,"twenty":18.128761,"median":26.319683,"eighty":33.522419,"marketCap":4224642740}],"updateTime":1747271370599}}}